Sotera Health Company 8-K Summary
Business Context and Reporting Period
Sotera Health Company filed a Form 8-K dated October 13, 2022, reporting events occurring on October 7 and October 12, 2022. The filing concerns changes to the company’s board of directors and does not report quarterly or annual operating results.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial performance metrics.
Material Changes
- Stephanie M. Geveda resigned as a director effective October 7, 2022, in connection with her departure from Warburg Pincus LLC.
- Ms. Geveda stated that her resignation did not result from any disagreement with the company, management, or the Board.
- On October 12, 2022, the Board appointed Robert B. Knauss, a Managing Director at Warburg Pincus, as a Class III director. His term is expected to expire at the 2023 annual meeting of stockholders.
- Mr. Knauss was deemed independent under Nasdaq rules and will enter into the company’s customary director indemnification agreement.
- The appointment was made pursuant to Warburg Pincus’s designation rights under the Stockholders Agreement.
- Mr. Knauss will receive compensation under the company’s non-employee director compensation policy, generally consisting of an annual cash retainer and an annual restricted stock unit grant.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, material contingencies, or unusual financial items. It notes that funds affiliated with Warburg Pincus and GTCR LLC beneficially owned shares representing a majority of the company’s outstanding common stock, as previously disclosed in the company’s proxy statement.
Investor Verification Checklist
- Verify the effective resignation date of Stephanie M. Geveda and the appointment date of Robert B. Knauss.
- Review the Stockholders Agreement for Warburg Pincus’s director designation rights and related ownership thresholds.
- Review the company’s proxy statement for beneficial ownership, director compensation, and related-party disclosures.
- Confirm that the change does not alter the company’s financial guidance or operating outlook, as no such information is included in this filing.